Identification and Validation of Functional Biomarkers for Keratoconus

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

There is currently no medication for containing KC, nor any adequate biomarkers to predict the disease. Furthermore, there is considerable confusion in the field regarding the pathophysiology of the disease and involvement of inflammation. To that end, this study is designed to address some of these questions by determining the proteomic profiles of KC patients with different clinical grades. This relatively large cohort study is expected to yield significant information regarding the molecules that are deregulated during progression of KC and may provide a framework to assign diagnostic biomarkers and therapeutic intervention points.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Narayana Nethralaya
• Collaborator: Singapore Eye Research Institute
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Evidence of corneal thinning by any type of keratometry

Exclusion Criteria:

• Corneal inflammation without evidence of ectasia

• Retinal disorder subjects excluded